Resveratrol reduces muscle atrophy and stress pathway activation in a combined disuse-hypoxia-mouse model

Read full text
Authors: Aziz Ahmad Khan, Sajid Khan Sadozai, Fawad Ali, Nemat Khan, Rizwan Qaisar
Cited by: 0
References: 41

Abstract

Introduction: Mechanical disuse and hypoxia synergistically worsen muscle atrophy by activating apoptosis, necroptosis, and ER stress pathways. While resveratrol, a natural polyphenol, has shown protective effects in isolated disuse or hypoxia models, its efficacy under combined conditions remains unclear. Methods: ) and treated daily with placebo or resveratrol (20 or 40 mg/kg) for two weeks. Muscle mass, grip strength, cling time, and gene expression of apoptotic, necroptotic, and ER stress markers were assessed. Results: HU-hypoxia significantly reduced muscle mass and function, with upregulation of stress-related genes. Resveratrol showed dose-dependent protection: 20 mg/kg modestly reduced atrophy, while 40 mg/kg nearly preserved muscle mass and strength to control levels under both normoxic and hypoxic conditions. To our knowledge, this is the first study to demonstrate protective effects of resveratrol in a combined HU and hypoxia model of muscle atrophy, accompanied by modulation of apoptosis, necroptosis and ER stress related gene expression. Conclusion: These results suggest that resveratrol may decrease muscle degradation in fast twitch dominant muscles under combined disuse and hypoxia. However, these results are restricted to gastrocnemius muscle in mice, and further investigations in slow twitch muscles and clinical models are required before clinical relevance can be confirmed. These findings support its potential as a therapeutic agent for muscle loss in clinical and spaceflight settings, warranting further translational research.

Fields of Study & Subjects

Muscle Physiology and Disorders Sirtuins and Resveratrol in Medicine Spaceflight effects on biology

Publication details

Journal / source
Frontiers in Pharmacology
Volume
17
Pages
1753486–1753486
Publication date
12 February 2026
Language
EN